Trial Profile
A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2009 Planned end date changed from 1 Mar 2007 to 1 Mar 2009 as reported by ClinicalTrials.gov.
- 22 Jan 2008 Status change from recruiting to in progress, from clinicaltrials.gov record.